Oxtellar XR (Oxcarbazepine) Patent Expiration, LOE Window & CMS Spending
Oxtellar XR (Oxcarbazepine) by Supernus: FDA Orange Book LOE 2027-04-13, 3 AB generics, $90.9M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Supernus |
| FDA Application & Pathway | N202810 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-04-13 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 3 |
| 2024 CMS Total Public Spend | $90.9M |
| 2024 Medicare Part D Spend | $28.5M |
| 2024 Medicaid Spend | $62.4M |
| Reported Wholesale Price Change (CA SB 17) | 9 WAC filings (max 19.1% 2-yr change) |